Metronidazol Genfar

Quick links

Choose a section

Quick links to important sections

Advertisements
Advertisements

Overview of Metronidazol Genfar

Metronidazol Genfar is the trade name for a specific generic medication containing the active ingredient Metronidazole, a synthetic compound recognized for its highly specific anti-infective properties. The drug entity is classified as a Nitroimidazole Antimicrobial Agent.

Property Description
Active ingredient Metronidazole
Form Tablets, Oral Suspension, Injectable Solution, Topical Forms
Pharmacological class Nitroimidazole Antimicrobial Agent
Common spectrum Anaerobic Bacteria and Protozoa
Origin Synthetic (chemically manufactured)

What Type of Medicine is Metronidazol Genfar? (Identity and Classification)

Metronidazol Genfar is accurately categorized as an agent with a dual classification, functioning effectively as both an antibiotic and an antiprotozoal agent. This unique dual-spectrum of action is directly conferred by its core structure as a Nitroimidazole derivative. This compound is clinically recognized for its efficacy against infections caused by several parasites, including Trichomonas vaginalis and Giardia lamblia. The medication is widely recognized for its therapeutic importance in global healthcare.

Composition, Origin, and Available Forms (Composition and Form)

The active component, Metronidazole, is a synthetic substance, having been chemically manufactured rather than derived from natural sources. Metronidazol Genfar, as a generic product, adheres strictly to the formulation containing the single-active ingredient. To ensure effective delivery across different infection types, the drug entity is available in various dosage forms, including tablets and oral suspension for systemic administration via the oral route. It is also available as an injectable solution for intravenous use, and in local formulations such as a topical cream.

General Purpose of Metronidazole Therapy (High-Level Purpose)

The primary purpose of Metronidazole is the targeted eradication of specific, susceptible pathogens where its mechanism of action is effective. It serves as a mainstay for addressing typical use scenarios like anaerobic bacterial infections and protozoal infections. This action is based on a principle of selective toxicity, whereby the compound becomes activated only inside the pathogen, causing structural damage. This function supports the clearance of conditions caused by a focused range of anaerobic bacteria and protozoa.

Regulatory References

  1. NIH MedlinePlus Metronidazole
  2. NIH NCBI StatPearls Metronidazole
Advertisements

What side effects are possible with Metronidazol Genfar?

Possible Side Effects and Safety Information

The safety profile for Metronidazole-containing products is organized according to regulatory classifications based on the affected physiological system and the frequency of occurrence.

Adverse Reactions and Frequency

Side effects categorized as Common in official documents frequently affect the Gastrointestinal System, including nausea, vomiting, diarrhea, abdominal pain, and the presence of an unpleasant metallic taste. Reactions categorized across the Nervous System as common include headache and dizziness.

More significant adverse reactions are classified as Rare or Very Rare. These include central nervous system effects such as encephalopathy, convulsive seizures, and cerebellar syndrome (impairment of coordination). The safety profile notes that peripheral neuropathy may occur, particularly with prolonged or high-dose exposure.

Serious reactions documented in regulatory sources also involve the Blood and Lymphatic System (e.g., leukopenia) and Skin (e.g., severe hypersensitivity or Severe Cutaneous Adverse Reactions like Stevens-Johnson Syndrome).

Safety Considerations and Restrictions

Official labeling contains specific warnings and constraints. The FDA label includes a Boxed Warning regarding evidence of carcinogenic activity in animals, limiting the drug's use to approved indications. Additionally, a strict restriction against consuming alcohol or products containing propylene glycol is documented during therapy and for at least three days afterward, due to the risk of a severe disulfiram-like reaction.

Population-specific safety notes apply, such as the need for dose reduction and monitoring in patients with severe hepatic impairment. Furthermore, the drug is officially contraindicated in patients with Cockayne syndrome, owing to the documented risk of severe, fatal hepatotoxicity.

Advertisements

Overdose and Emergency Response

Overdose and when to seek help: Official Regulatory Information

The official overdose profile for Metronidazol Genfar is based on reports of both accidental overdoses and exposures from prolonged, high-dose administration. Single oral exposures, including doses up to 15 g, have been documented, with reported manifestations primarily affecting the gastrointestinal and nervous systems [1.1].

Overdose Presentations (Documented) Severe Outcomes (Reported)
Nausea and Vomiting Convulsive Seizures
Ataxia (lack of muscle coordination) Peripheral Neuropathy (numbness, tingling)

The most serious outcomes documented in regulatory labeling include Convulsive Seizures and Peripheral Neuropathy, which are mainly associated with extended high-dose exposure [1.6].

Emergency Response and Management

There is no specific antidote known for metronidazole overdose [1.6]. Therefore, the official regulatory approach to management consists entirely of symptomatic and supportive therapy. In cases of overexposure, urgent medical help must be sought immediately. Government guidance advises contacting emergency services if the victim has collapsed, had a seizure, has trouble breathing, or cannot be awakened [1.3]. Additionally, given the drug's elimination profile, monitoring for Metronidazole-associated adverse events is recommended for patients with end-stage renal disease, particularly those undergoing hemodialysis, as this procedure removes significant amounts of the drug [2.3].

Advertisements

Therapeutic Uses of Metronidazol Genfar

What Metronidazol Genfar Treats: Main Uses and Benefits

Metronidazol Genfar is commonly used to help manage symptoms related to physical discomfort and systemic imbalance stemming from certain infections. It is applied in clinical settings that involve acute or unstable symptom patterns, primarily across domains where additional symptomatic support is needed against anaerobic bacteria and protozoal parasites.

Conditions where the medication is relevant include serious systemic infections like septicemia and deep abscesses; parasitic diseases such as Amebiasis and Giardiasis; urogenital issues like Trichomoniasis and Bacterial Vaginosis; and severe C. difficile colitis. In these situations, the medication helps address symptom clusters that may become intense or disruptive, supporting the patient during difficult episodes by easing distress.

“The drug is applied in scenarios where additional management of discomfort is required, especially when symptoms interfere with routine activities.”

It is generally used to provide supportive relief when symptoms intensify, and may also be part of short-term symptomatic assistance to assist in the symptomatic management of potential infection during specific surgical procedures.

Quick Fact: Support for Anaerobic Infection Symptoms
This medicine assists with managing fever, localized pain, and systemic discomfort associated with deep-seated infections.
Advertisements

Eligibility and Restrictions for Use

Who Can and Cannot Use Metronidazol Genfar?

Eligibility for metronidazole use is strictly governed by regulatory classifications detailing contraindications and conditional restrictions.

Absolute Contraindications: The medicine must not be used by patients with a history of hypersensitivity to metronidazole or other nitroimidazole derivatives. Use is also prohibited in patients with Cockayne Syndrome due to the risk of fatal liver failure. Patients must abstain from alcohol, propylene glycol, and disulfiram for specified regulatory timeframes before, during, and after treatment.

Conditional Restrictions: Patients with severe hepatic impairment (Child-Pugh C) typically require a 50% dose reduction and close monitoring. Use in patients with End-Stage Renal Disease (ESRD) requires monitoring for adverse events due to metabolite accumulation. Caution is also advised for those with a history of blood dyscrasias or certain Central Nervous System (CNS) diseases.

Age and Reproductive Status: Use is contraindicated for the treatment of Trichomoniasis during the first trimester of pregnancy. Furthermore, official guidance recommends that women temporarily discontinue breastfeeding for 12 to 24 hours after a single-dose treatment. Safety and effectiveness are not established for all indications in the pediatric population, such as treating vaginal infections in unmenstruated girls.

Advertisements

What should I know about interactions with other medicines?

Interactions with other medicines and products

This section strictly details the officially documented interaction profile of Metronidazole as defined by government regulatory documents.

Interacting Substance/Class Official Interaction Outcome Timing Restriction
Alcohol / Propylene Glycol Contraindicated. Risk of a disulfiram-like systemic reaction. Avoid consumption during and for at least 3 days after therapy.
Disulfiram Contraindicated. Risk of psychotic reactions. Must not be administered within two weeks of Disulfiram use.
Oral Coumarin Anticoagulants Potentiation of anticoagulant effect, leading to prolongation of Prothrombin Time (INR). INR must be monitored upon co-administration.

Metronidazole formally affects the pharmacokinetics of several other medicines by altering clearance. It is documented to reduce the clearance of agents such as Busulfan and 5-Fluorouracil, which increases the plasma exposure and potential toxicity of these co-administered drugs. Lithium clearance is also impaired, resulting in retention and increased serum concentrations. Conversely, medicines like Phenytoin and Phenobarbital can accelerate the clearance of Metronidazole itself, reducing its plasma half-life. Accumulation of Metronidazole is also a documented risk in patients with severe hepatic impairment, which heightens the potential for drug interactions.

Advertisements

Mechanism of Action

Activation by Anaerobic Enzymes

Metronidazole, a prodrug, enters microbial cells via passive diffusion. Its activation occurs exclusively in environments with low oxygen levels. Inside susceptible anaerobic bacteria and protozoa, specific electron-transport proteins (such as ferredoxin) donate electrons to the drug's nitro group, initiating a molecular reduction. The pathway specificity ensures that the reduction occurs predominantly within these microorganisms, limiting activation in aerobic human cells.


DNA and Nucleic Acid Disruption

The resulting short-lived, highly reactive nitroso radicals and other reduced metabolites are the drug's primary mechanistic agents. These highly reactive molecules directly interact with the microorganism's DNA, causing strand breakage and destabilization of the helical structure. This molecular modification prevents essential nucleic acid synthesis, thereby blocking DNA replication and transcription, resulting in the irreversible inhibition of vital cellular functions.


Cell Function Dysregulation

The reduction process consumes intracellular electrons and alters the drug molecule, creating a concentration gradient that promotes continued drug uptake into the microbial cell. This sustained high concentration, combined with the cytotoxic radicals, results in the inhibition of protein synthesis and subsequent disruption of cellular integrity.

Advertisements

Dosage and Administration Information

The usage of Metronidazol Genfar is determined by administration guidelines focusing on route, dose, and frequency. The medicine can be administered via oral forms (tablets, suspension), as an Intravenous (IV) solution, or in topical formulations.

For systemic anaerobic infections, the standard regimen starts with a loading dose of 15 mg/kg followed by a maintenance dose of 7.5 mg/kg, administered every 6 hours, with the daily dosage not exceeding 4 g. Fixed oral doses, such as 750 mg three times daily, are specified for certain parasitic conditions like amebiasis.

Administration Scope

Feature Standard Administration Protocol
Timing in relation to meals Immediate-release forms may be taken with food. Extended-release tablets must be taken on an empty stomach (1 hour before or 2 hours after a meal).
Population-specific adjustment The dose must be reduced by 50% to 67% in patients with severe hepatic impairment. A supplementary dose is required after hemodialysis sessions.
Special procedural conditions The IV infusion must be administered slowly over a 30 to 60-minute period. Extended-release tablets must be swallowed whole and cannot be crushed or chewed.
Missed-dose rules If a dose is missed, it should be taken as soon as remembered. If it is nearly time for the next dose, the missed dose is skipped; doses must not be doubled.

Connection to the Overall Use Protocol

These instructions define the structured protocol for Metronidazole use by standardizing the route of delivery and specifying exact dose calculations and frequency patterns. These guidelines ensure consistency by establishing parameters for the timing of intake, preparation of the IV form, and adherence to defined treatment durations, typically 7 to 10 days for systemic use.

Advertisements

Recent Clinical Evidence

Recent Clinical Evidence Overview

Metronidazole, the active ingredient in Metronidazol Genfar, is a widely established antibiotic primarily studied for its role against anaerobic bacterial infections and certain parasitic protozoa. Research across multiple clinical trials continues to examine its utility, particularly in complex infection settings and with different dosing schedules.

Efficacy in Key Indications

Clinical trials consistently document the use of metronidazole for trichomoniasis, amebiasis, and various anaerobic bacterial infections (e.g., Bacteroides and Clostridium species). Studies have explored different regimens, such as single-dose therapy for trichomoniasis, compared to extended, multi-day courses, with observed cure rates varying by regimen and patient adherence.

Studies on Dosing and Formulation

Recent research has focused on optimizing metronidazole administration. For example, in intra-abdominal infections, trials have compared an every-8-hour (q8h) dosing interval against an extended every-12-hour (q12h) interval. Findings from one multi-center study suggested that the extended interval had comparable clinical cure outcomes, but required increased monitoring for certain patients.

Another area of investigation involves modified formulations. Delayed-release capsules are being examined in studies to assess if they can increase drug concentration locally in the colon, which is a target for treating conditions such as Clostridioides difficile infection (CDI).

Emerging and Combination Use

Metronidazole remains a component in combination therapies for specific conditions, including Helicobacter pylori eradication and pelvic inflammatory disease (PID). Furthermore, research is ongoing to evaluate its use in non-infectious conditions where anaerobic bacteria may play a role, such as certain complex intestinal disorders. For example, trials are currently assessing its use in combination with other agents for conditions like chronic pouchitis.

Key Studies & References

  1. Single-dose versus 7-day-dose metronidazole for the treatment of trichomoniasis in women: an open-label, randomised controlled trial
  2. Assessing Clinical Outcomes of Metronidazole for Intra-Abdominal Infections When Dosed Every 12 h Versus Every 8 h in a Multi-Center Health System
  3. Study of Metronidazole Delayed-Release Capsules in Comparison With Immediate-Release Tablets (Flagyl) for Safety and Pharmacokinetics (NCT07251127)
  4. Metronidazole (StatPearls - NCBI Bookshelf) (Dosing and Combination Therapy Overview)
Advertisements

Frequently Asked Questions (FAQ)

Common questions about Metronidazol Genfar (FAQ)


Q: Why do some people experience a metallic taste with this medicine?

The metallic taste is a common side effect frequently reported in official drug labels. This effect is believed to be caused by small amounts of Metronidazole or its breakdown products (metabolites) being secreted into the saliva, which directly exposes the taste receptors.


Q: Are there specific foods or supplements that are officially described as interacting with Metronidazol Genfar?

The official product information contains a strict warning regarding consuming alcohol due to the risk of a severe systemic reaction. The medication is also noted to interact with specific herbal products, such as St. John's Wort, and certain over-the-counter stomach acid reducers, like cimetidine.


Q: What is the main difference between Metronidazole and an anti-fungal medicine?

Metronidazole is officially classified as an antibiotic and antiprotozoal medication, meaning it is specifically designed to work against certain anaerobic bacteria and parasites. Anti-fungal medicines, by contrast, are used to treat infections caused by fungi, and Metronidazole is not effective against that class of organisms.


Q: What is the most important piece of safety information about Metronidazol Genfar?

The highest-level safety information in the drug label is the Boxed Warning, which cites evidence from animal studies suggesting carcinogenic (cancer-causing) potential. Official guidance states that the medication’s use is limited to its approved and specific indications. There is also an absolute contraindication regarding the consumption of alcohol.


Q: Is Metronidazol Genfar effective against viruses?

No, official product information indicates that Metronidazole is an antibiotic and antiprotozoal agent and will not work against common viral infections like the cold or flu. It targets only infections caused by specific susceptible bacteria and parasites.


Q: What research evidence exists regarding long-term safety of Metronidazol Genfar?

The drug label includes a Boxed Warning that highlights the carcinogenic potential observed in animal studies. This warning is a key regulatory constraint which limits the drug’s use to only approved indications, intended to mitigate potential risks.


Q: Is Metronidazol Genfar known to cause tiredness or drowsiness?

Regulatory warnings advise that the drug may cause nervous system side effects such as dizziness and drowsiness (feeling sleepy). Official guidance notes these effects may affect a person’s ability to safely engage in activities requiring mental alertness, such as driving or operating machinery.


Q: Does the time of day a person takes Metronidazol Genfar matter?

Official dosing guidance focuses on the interval between doses rather than the time of day itself. Regulatory documents indicate that if multiple doses are prescribed, they should be spaced evenly throughout the day (for instance, every 8 hours) to help maintain a consistent level of the medicine in the blood.


Q: Does Metronidazol Genfar treat fungal infections too?

No, official regulatory information confirms that Metronidazole is not effective against fungal infections. It is classified specifically as an antibiotic and antiprotozoal agent used to treat infections caused by specific bacteria and parasites.


Q: How quickly does Metronidazol Genfar typically start to work?

The medicine typically begins the process of working a few hours after the first dose is taken. However, patients may not feel better or notice significant symptom relief for a few days. Completing the full course is considered essential for achieving the best clinical outcome.


Q: Can Metronidazol Genfar affect the results of certain medical lab tests?

Yes, official documents state that Metronidazole may interfere with the results of certain common medical laboratory tests. This interference can include tests that check liver function and various enzyme levels, potentially leading to inaccurate readings.


Q: Can Metronidazol Genfar cause changes in urine color?

Yes, official regulatory information reports that the drug can cause the urine to turn a dark or reddish-brown color. This change is considered harmless and is due to a natural process where a breakdown product (metabolite) of the medicine is excreted from the body.


Q: What happens if a person stops taking Metronidazol Genfar early?

Regulatory guidance notes the importance of completing the entire prescribed course. Stopping treatment too soon carries the risk that the infection may not be fully cleared, potentially allowing the infection to return and increasing the chance of developing drug-resistant bacteria or parasites.


Q: Is Metronidazol Genfar used for dental infections?

Yes, official indications note that Metronidazole is used to treat various infections of the mouth, including infected gums and dental abscesses. This use is specifically targeted at infections caused by susceptible anaerobic bacteria.


Q: What are the official guidelines for driving or operating machinery while taking this drug?

Official regulatory sources caution that the drug may cause nervous system side effects, such as dizziness, confusion, or visual disturbances, which can impair a person's ability to drive or operate heavy machinery. Guidance suggests avoiding these activities if such symptoms are experienced.


Q: Why is it important to complete the entire prescribed course of Metronidazol Genfar?

Completing the full course, even if symptoms begin to improve, is considered necessary to ensure the infection is completely cleared from the body. This practice helps prevent the infection from returning and reduces the chance of the pathogens developing resistance to the medication.


Q: Does Metronidazol Genfar interact with birth control pills?

Official drug labels indicate that Metronidazole may potentially make oral birth control pills (contraceptives) containing ethinyl estradiol less effective. Regulatory guidance notes that alternative or additional non-hormonal contraception may be considered.


Q: What should be done if an overdose of Metronidazol Genfar is suspected?

Official guidance states that there is no single specific antidote for an overdose of Metronidazole. Treatment involves general supportive measures in a clinical setting, and activated charcoal may be used to help remove any unabsorbed drug from the body.


Q: Does Metronidazol Genfar cause sensitivity to sunlight?

Official product information for the topical form of the drug includes a caution to avoid or minimize exposure of the treated area to strong sunlight or other sources of UV light. This regulatory caution is typically noted for skin-applied medications.


Q: Can Metronidazol Genfar be taken with antacids?

The drug's interaction profile notes that it may interact with specific types of acid-reducing medications, such as cimetidine (an H2 blocker), which can sometimes be available over the counter. This interaction may potentially increase the amount of Metronidazole in the bloodstream.


Q: Are there any known interactions between Metronidazol Genfar and herbal supplements like St. John's Wort?

Yes, regulatory interaction information notes that certain herbal supplements, such as St. John's Wort, have been associated with a potential risk of interaction. This type of interaction may affect heart rhythm when the herb is taken concurrently with Metronidazole.


Q: Are there any official restrictions on using Metronidazol Genfar for people over 65?

Official labeling advises that use in elderly patients may require caution and potential dose adjustments. This is often due to expected age-related changes in the body's ability to process the medicine (pharmacokinetics), and monitoring of drug levels may be necessary.

Advertisements

How should Metronidazol Genfar be stored and disposed of?

How to Store and Dispose of Metronidazole (Metronidazol Genfar)

Official labeling defines precise conditions for storing and disposing of Metronidazole to maintain product stability and safety.

Storage Requirement Official Regulatory Statement
Temperature Store at Controlled Room Temperature, 20 C to 25 C (68 F to 77 F). Do not freeze.
Protection Must be Protected from light, away from excess heat and moisture.
Container Keep in a tight, light-resistant container with a child-resistant closure.
Child Safety Store medication out of the sight and reach of children.

Disposal Instructions

Unused or expired Metronidazole must be disposed of in accordance with local regulations. Environmental guidelines prohibit allowing the product to enter sewers or any body of water.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Metronidazol Genfar found in:

A-Z Index: